Kornimate/medical-research-clean huggingface dataset:
long acting cabotegravir plus rilpivirine in people living with hiv-1 aged ≥ 60 years for 24 months.

Conditions: HIV-1 Infected Adults with Controlled Viremia

Summary: people living with hiv-1 (plhiv) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (art), allowing them to stabilize the hiv-infection and to live a normal life despite the infection. the present study is encouraged to demonstrate that efficacy and security of cab la + rpv la treatment's on this population remains the same compared to younger population of patients. this study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.


Eligibility criteria:
inclusion criteria: * be able to understand and comply with protocol requirements, instructions, and restrictions. * understand the long-term commitment to the study and be likely to complete the study as planned. * be considered appropriate candidates for participation in an investigative clinical trial with oral and intramuscularly injectable medications (e.g., no active substance use disorder, acute major organ disease, or planned long-term work assignments out of the country, etc.). * must be on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the nnrti and ini class. * plasma hiv-1 rna \<50 copies/ml at screening. * a female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum hcg test at screen and a negative urine hcg test at randomization) and not lactating exclusion criteria: * plasma hiv-1 rna measurement ≥50 copies/ml within 6 months prior to screening. blips are allowed (increased viral load ≥50 copies/ml but \<200 copies/ml preceded and followed by a viral load less than 50 copies/ml) * any drug holiday during the window between initiating first hiv art and 6 months prior to screening, except for brief periods (less than 1 month) where all art was stopped due to tolerability and/or safety concerns. * any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to nnrti or insti (defined as a confirmed plasma hiv-1 rna measurement ≥200 copies/ml after initial suppression to \<50 copies/ml while on first line hiv therapy regimen) * subjects who are currently participating in or anticipate being selected for any other interventional study. observational studies and intervention studies that do not include treatments are allowed unless they interfere with scheduled visits. * participants receiving any prohibited medication and who are unwilling or unable to switch to an alternative medication
timing for removal of chest tubes in adult cardiac surgery

Conditions: Heart Surgery; Chest Tube; Effusion Pleural; Pain, Postoperative

Summary: rationale: evidence regarding the timing of chest tube removal after cardiac surgery is sparse. the timing of chest tubes removal constitutes a balancing act between risk of retained blood syndrome, infection, patient discomfort and opioid-related side effects. several studies have shown that chest tubes can safely be removed on the first postoperative day compared to later. a single retrospective study raised concern as chest tube removal on the day of surgery was associated with an increased requirement of drainage of pleural effusions. primary objective: to compare the impact of two standard chest tube removal protocols following open-heart surgery on the incidence of pleural and/or pericardial effusion requiring invasive drainage secondary objectives to evaluate the impact of chest tube removal on the day of surgery (day0) compared to the first postoperative day (day1) regarding: * comsumption of analgetic drugs * early postoperative pain * incidence of infection * early postoperative respiratory function study design: single-center, open, parallel-group, prospective, cluster-randomized controlled trial alternate assignment of chest tube removal according to day 0 versus day 1 protocol based upon the month of surgery (even versus odd months). study population: 1300 consecutive patients undergoing elective open heart surgery in full or lower hemisternotomy with or without cardiopulmonary bypass including coronary artery bypass grafting, valve surgery, simple aortic surgery or combinations.


Eligibility criteria:
inclusion criteria: all consecutive patients undergoing elective open heart surgery in full or lower hemisternotomy with or without cardiopulmonary bypass including coronary artery bypass grafting, valve surgery, simple aortic surgery or combinations. exclusion criteria: cardiac procedures deemed not eligible to chest tube removal on the day of surgery due to increased bleeding risk due to: * procedures in hypothermic circulatory arrest * previous cardiac surgery * procedures performed through upper hemisternotomy * emergent treatment required (\< 24 hours) * non-aspirin antiplatelet drugs stopped \< 5 days preoperatively (clopidogrel, prasugrel, ticagrelor, ticlopidine) * current use of vitamin k antagonists or new oral non-vitamin k anticoagulants * platelet count \> 450 or \<100 x 109/l prior to surgery

Keywords: surgery, heart chest tube effusion, pleural complications, postoperative pain, postoperative
the impact of social phone calls with isolated older adults receiving protective services for abuse, neglect and/or exploitation

Conditions: Senior Abuse

Summary: the purpose of this study is to see the the impact of social visits, through weekly phones calls, on quality of life outcomes of depression, anxiety, loneliness, isolation and self-rated health for older adults visited by adult protective services (aps) for abuse, neglect and/or exploitation (ane) and to also to determine the benefit of these conversations on the medical student's perspective of aging and ane.


Eligibility criteria:
inclusion criteria: * recently visited by texas adult protective services for abuse, neglect and/or exploitation * living in harris county or a surrounding county serviced by aps district 6 * substantiated elder mistreatment (i.e. psychological abuse, financial exploitation, sexual abuse, neglect, physical abuse) and/or self neglect * provide a signed or verbal release agreeing to be contacted by the volunteers * able to provide verbal consent to participate in the study exclusion criteria: * significant cognitive impairment or incapacity as determined by their inability to complete the consent steps * non-english-speaking

Keywords: depression anxiety loneliness isolation adult protective services
study of pazopanib, paclitaxel, and carboplatin in patients with advanced solid tumors

Conditions: Unspecified Adult Solid Tumor - Protocol Specific; Breast Cancer - Female

Summary: this is an open label, dose escalation study to determine the safety and tolerability and maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors.

this is an open label, dose escalation study to determine the maximum tolerated dose (mtd) of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors. there will be a dose expansion cohort of thirty patients to assess detailed pharmacokinetics and to assess any signal of activity in patients with solid tumors and in a portion who have breast cancer that is triple negative (er-negative, pr-negative, and her2-negative).

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of a solid malignancy with advanced disease that has relapsed, that is refractory to standard therapies, or for which there is not standard therapy, or for which the patient opts not to receive standard therapy. * at the recommended phase ii dose level, triple-negative breast cancer defined as er-negative, pr-negative, and her2-negative, will be enrolled and another 10 patients with a solid malignancy who would benefit from a paclitaxel and carboplatin-based regimen, will also be enrolled. * male or female ≥ 18 years of age * able to swallow and retain oral medications exclusion criteria: * major surgery within last 28 days or cytotoxic chemotherapy, biologic therapy, investigational agents, or radiotherapy within last 21 days. patients who have completed therapy with mitomycin c or nitrosurea will have to wait 42 days. * more than 3 prior lines of cytotoxic chemotherapy for metastatic disease
oral antibiotics after obstetric perineal tear

Conditions: Obstetric Trauma; Infections; Wound Dehiscence

Summary: the purpose of this study is to investigate if 3 dose of oral antibiotics administrated the first day after a vaginal delivery with a second degree obstetric tear will decrease the risk of infection and/or wound dehiscence compared to women with 3 doses of placebo treatment.

background: obstetric tear occurs in more than 90% of nulliparous women and up to 25% subsequently experience wound dehiscence and/or infection. some data shows that intravenous antibiotics given during delivery reduces this risk. it is unknown if oral antibiotics given after delivery can reduce the risk of wound dehiscence or infection. the study-goupe want to investigate whether three doses of antibiotics (amoxicillin 500 mg / clavulanic acid 125 mg) given after delivery can reduce the risk of wound dehiscence and infection. methods: the investigators will perform a randomized, controlled, double-blinded study and plan to include 221 women in each arm with allocation 1:1 in relation to the randomization. the study is carried out at department of obstetrics \& gynecology, herlev university hospital, copenhagen, denmark. the women will be included after delivery if they have had a second-degree tear or episiotomy. the first tabelt has to be taken with in 6 hours from the delivery. after inclusion, the women will have a clinical follow up visit after one week. the tear and healing will be evaluated regarding infection and/or dehiscence. the women will again be invited for a one year clinical examination including ultrasound. questionaries exploring symptoms related to the vaginal tear and possible complications will be answered at both visits. the primary outcome is wound dehiscence and/or wound infection, which will be calculated using χ2-tests to compare groups. secondary outcomes are variables that relate to wound healing, for example pain, use of painkillers, need for further follow-up, as well as other outcomes that may be related to the birth or healing process; urinary or anal incontinence, symptoms of prolapse, female body image and sexual problems. discussion: reducing the risk of wound dehiscence and/or infection would decrease the number of control visits, prevent the need for longer antibiotic treatment and possibly also decrease both short-term and long-term symptoms. this would be of great importance since the period after a delivery is a crucial time for the whole family.

Eligibility criteria:
inclusion criteria: * danish speaking women above 18 years * second degree perineal tear and/or episiotomy * suturing of obstetric tear at herlev hospital exclusion criteria: * allergies to the treatment. * women who end up with a cesarean-section, including those who have obstetric tears that require stitching or have had an episiotomy * women who receive antibiotics intra- or postpartum for other reasons.

Keywords: obstetric tear women's health antibiotics infection wound dehiscence
multiple antigen specific cell therapy (masct) for hepatocellular carcinoma(hcc) patients after radical resection or radio frequency ablation(rfa).

Conditions: Hepatocellular Carcinoma

Summary: to prove that the efficacy and safety of 'masct group' is superior to 'non-treatment group' in patient undergone curative resection (rfa or operation) for hepatocellular carcinoma in china.


Eligibility criteria:
inclusion criteria: 1. the patient is diagnosed as hepatocellular carcinoma(hcc); 2. the patient underwent radical operation of hcc within 8 weeks before enrollment; 3. the number of tumors≤2； 4. no cancer embolus in the main portal vein and first branch, hepatic duct and first branch, hepatic vein, inferior vena cava; 5. no portal lymph node metastasis； 6. no extra-hepatic metastasis; 7. complete tumor resection without residual tumor at the surgical margins should be confirmed by enhanced ct or mri imaging within 4 week (including 4 weeks) after radical operation; 8. if an increased serum afp level was detected of the patient before the radical operation, the afp level should be returned to normal in 8 weeks; 9. child-pugh score ≤9; 10. ecog performance status (ecog-ps) ≤2 ; 11. the expected survival time \> 2 years; 12. tests of blood,liver and kidney should meet the following criteria： * wbc\>3×109/l * neutrophil counts \>1.5×109/l * hemoglobin ≥85 g/l * platelet counts≥50×109/l * pt is normal or the extend time \<3s * bun≤1.5 times the upper-limit , * serum creatinine≤ 1.5 times of the upper-limit 13. sign the informed consent. exclusion criteria: 1. women who is pregnant or during breast feeding or plan to pregnant in 2 years; 2. extra-hepatic metastasis or liver residual tumor; 3. cancer embolus in the main portal vein and first branch, hepatic duct and first branch, hepatic vein, inferior vena cava; 4. 6 months before enrollment: the period of systemic and continuous use of immunomodulatory agents (such as interferon, thymosin, traditional chinese medicine) was longer than 3 months; 5. 6 months before enrollment: the period of systemic and continuous use of the immunosuppressive drugs (such as corticosteroids drug) was longer than 1 months; 6. received any cell therapy (including nk, cik, dc, ctl, stem cells therapy) in 6 months before enrollment; 7. positive for hiv antibody or hcv antibody; 8. have a history of immunodeficiency disease or autoimmune diseases (such as rheumatoid arthritis, buerger's disease, multiple sclerosis and diabetes type 1); 9. patient who suffered from other malignant tumor in 5 years before enrollment (except skin cancer, localized prostate cancer or cervix carcinoma); 10. . patients with organ failure; 11. patients with serious mental disease; 12. drug addiction in 1year before enrollment (including alcoholics); 13. participated in other clinical trials in 3 months before screening; 14. other reasons the researchers think not suitable.

Keywords: hcc dc ctl
nafld study: us vs liver biopsy

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of nafld and nash in 20 obese patients (bmi\> 30) candidates for laparoscopic bariatric surgery and / or cholecystectomy


Eligibility criteria:
inclusion criteria: 1. patients who are candidates for bariatric surgery between the ages of 18 and 65, * bmi\> 40 kg / m2, in the absence of any other comorbidity * bmi\> 35 kg / m2, in the presence of comorbidities among those classically considered to be associated with obesity * icm\> 30 kg / m2, in the presence of t2dm not in glycometabolic compensation 2. patients who are candidates for laparoscopic cholecystectomy for symptomatic calculi with bmi\> 30 exclusion criteria: * age ≤ 18 or ≥ 65 * any concurrent surgical procedure except cholecystectomy and hiatal hernia repair * conversion into laparotomy surgery * post-operative complications requiring new surgical treatment * patient not compliant in the follow-up
surviving pneumonia

Conditions: Community-acquired Pneumonia

Summary: the study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (cap). during a 5-year study period, all patients (aged ≥ 18 years) admitted with cap at north zealand hospital will be invited for inclusion. questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. the main clinical outcomes of the study consist of deaths and development of diabetes.


Eligibility criteria:
inclusion criteria: * infiltrate on chest radiograph plus one or more of the following: * fever (temperature, ≥38.0°c) * hypothermia (\<35.0°c), * new cough with or without sputum production * pleuritic chest pain * dyspnea * altered breath sounds on auscultation. exclusion criteria: * patients unable to give informed consent * patients unwilling to give informed consent

Keywords: community-acquired pneumonia diabetes immune status nutritional status physical inactivity risk factors
study to evaluate the safety of the fixed-dose combination rosuvastatin/ezetimibe for patients with dyslipidaemia

Conditions: Dyslipidemias

Summary: retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medical practice.

to assess the safety of the fixed-dose combination of rosuvastatin / ezetimibe in subjects older than 18 years of age (gender indistinct) with dyslipidemia who at the discretion have been candidates for treatment with the combination. for the safety analysis, all the research subjects who have taken rosuvastatin / ezetimibe will be considered. the information recorded by the treating physicians in the file will be reviewed and within the case report format (crf) of all adverse events that occur in the study. the terms originally used in the case report format by the investigators to identify adverse events (ae) will be coded in the analysis stage of results using the current meddra dictionary. the incidence of ae will be synthesized such as the frequency count and percentage of research subjects with events adverse by organ / system.

Eligibility criteria:
inclusion criteria: * age\> 18 years of age. * diagnosis of dyslipidemia. * that treatment with the fixed-dose combination of rosuvastatin / ezetimibe is documented. * have security questioning on at least two occasions. exclusion criteria: * subjects who has taken any other statins, fibrates, bile acid sequestrants, niacin (\> 500 mg) or inhibitors of pcsk9 concomitantly during treatment with rosuvastatin / ezetimibe.

Keywords: dyslipidemias combine therapy lower cholesterol lipids
interest of catalepsy in the hypnotic trance

Conditions: Hypnosis

Summary: catalepsy seems to facilitate hypnotic induction and deepen hypnotic trance, although no work confirms the usefulness of this technique which is in common use in hypnosis. furthermore, it has been shown that the hypnotic trance state is accompanied by an increase in parasympathetic tone, the non-invasive measurement of which is easy by the ani monitor (analgesia nociception index). the research hypothesis is that, by adding a body dissociation, catalepsy could facilitate and intensify the hypnotic trance, the intensity of which can be monitored and is proportional to the parasympathetic tone.

after randomization, subjects will either benefit from the normal hypnotic trance, or from the hypnotic trance associated with catalepsy of the hand. t0 = installation in a sitting position and collection of an accompanying theme t1 = induction of the hypnotic trance (closing eyes) with restitution of the theme to the patient and suggestion of comfort over a period of 5 to 10 min t2 = validation of comfort by a pre-established signal t3 = return to consciousness (opening eyes) t4 = end of questionnaire about absorption, dissociation and time perception

Eligibility criteria:
inclusion criteria: * healthy volunteers * consent for participation * affiliation to the social security system exclusion criteria: * arrhythmia (atrial fibrillation, pacemaker, defibrillator) * autonomic nervous system disorder (paraplegia, epilepsy, etc.) * pregnant or breastfeeding woman * patients under protection of the adults (guardianship, curators or safeguard of justice) * communication difficulties

Keywords: hypnosis catalepsy parasympathetic tone absorption dissociation perception of time
impact of gut hormones and inflammatory adipokines in obese patients underwent bariatric surgery

Conditions: Obesity; Chronic Inflammation; Type 2 Diabetes

Summary: obesity and type 2 diabetes, dyslipidemia and related metabolic disease has become a threat to our national life and health which is showing a trend. bariatric surgery had been confirmed definite therapeutic effect to obesity and type 2 diabetes. however, laparoscopic gastric bypass and laparoscopic sleeve gastrectomy have the similar outcome to type 2 diabetes, but the two surgical methods and principles are completely different, which mechanisms are not yet clear. lots of literature report adipose tissue releases adipokines and inflammatory cytokines induced chronic inflammation and obesity-related complications (insulin resistance and type 2 diabetes).it is not clear whether to change these gastrointestinal hormones, adipokines and secretion of inflammatory cytokines with the operation, which play a therapeutic effect of obesity-related complications and diabetes. in addition, the investigators are wonder whether gut hormones, adipokines and inflammatory cytokines have some correlation in different severity obese patients,. it is worth to explore that could intestinal hormones, adipokines and inflammatory factors levels guide us to choice the different surgical approach to different severity obese patients. the investigators tried to investigate different surgical methods to alleviate diabetes and other metabolic diseases mechanisms though hormones and inflammatory factors and adipose tissue inflammation level and compare the impact of intestinal hormones and inflammatory adipokines of the two surgical approaches.


Eligibility criteria:
inclusion criteria: * according to the standard of obesity obesity task force established in 2001, bmi≥28k / m2 with obesity-related metabolic diseases in patients, or bmi≥35kg / m2 in patients with severe obesity were selected. * the age of 14-65 years. * self-capacity, non-drug dependence, psychological illness. * not prompted stomach ulcers, erosions, tumors, polyps, atrophic gastritis and other stomach diseases in the preoperative endoscopy. * no history of stomach and abdominal surgery. * case source: first affiliated hospital of jinan university, by the same team of doctors performed the surgical procedure. exclusion criteria: * whom did not follow the inclusion criteria

Keywords: obesity bariatric surgery gut hormones inflammatory adipokine